Clinical trials: ALS (Amyotrophic Lateral Sclerosis), open to volunteers
Amyotrophic Lateral Sclerosis
Analysis of Human ALS Tissues and Registry of ALS Patients
Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's Disease, is a progressive, terminal condition of muscle weakness that is associated with degeneration of neurons in the spinal cord and brain.
- Trial name
- NCT05067179
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Illinois Chicago
Amyotrophic Lateral Sclerosis (ALS)
A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.
The purpose of this trial is to learn about the effects of NB-4746 compared with placebo in people with amyotrophic lateral sclerosis.
- Trial name
- NCT07369076
- Testing
- NB-4746 High dose, NB-4746 Low dose, NB-4746 (Dose TBD)
- Where
- 12 sites in Australia, Canada and 2 more
- Volunteers
- 80 people
- Sponsor
- Nura Bio
Amyotrophic Lateral Sclerosis & Other Neuromuscular Disorders
Using Gaze to Enable Head-neck Movements in Patients With Head Drop
The investigators will develop and evaluate controllers for a powered neck exoskeleton in patients with amyotrophic lateral sclerosis (ALS) to understand how to allow adequate personalization and function and achieves…
- Trial name
- NCT07836751
- Testing
- neck exoskeleton controller
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Amyotrophic Lateral Sclerosis (ALS)
Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases
An open, multi- center phase Ⅰ clinical study evaluating the safety and efficacy of autologous human polyclonal regulatory T cell injection (NP001 cell injection) in patients with Neurodegenerative diseases (ALS).
- Trial name
- NCT06671236
- Testing
- Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Novabio Therapeutics
Amyotrophic Lateral Sclerosis (ALS)
The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects with Amyotrophic Lateral Sclerosis
- Trial name
- NCT07118319
- Testing
- Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)
- Where
- China
- Volunteers
- 12 people
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Paralysis; Quadriplegic, Quadraplegia
MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System
This research study is being done to develop a novel brain-computer interface (BCI) technology that can enable severely paralyzed individuals to interact with the world through direct brain-control of a computer.
- Conditions
- Paralysis; Quadriplegic, Quadraplegia, Tetraplegia, Tetraplegic Motor Dysfunction Following Brainstem or Spinal Cord Injury
- Trial name
- NCT05936619
- Testing
- Mind Extender (MindEx)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Nader Pouratian
Amyotrophic Lateral Sclerosis ALS7
The Importance of Positive Expiratory Pressure Associated With the In-exsufflator in ALS Patients
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder that impairs motor neurons, with a life expectancy of 2 to 7 years after diagnosis.
- Trial name
- PEPINEX (NCT06249412)
- Testing
- MI-E with PEP function activated during the pause, MI-E without PEP function activated during the pause
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Groupe Hospitalier du Havre
Anarthria, Dysarthria
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia
The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with…
- Conditions
- Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries
- Trial name
- BG-Speech-01 (NCT05724173)
- Testing
- BrainGate Neural Interface System
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Leigh R. Hochberg, MD, PhD.
Multiple Sclerosis, Amyotrophic Lateral Sclerosis
Polish Version Fatigue Severity Scale
Fatigue is one of main symptoms in multiple sclerosis, amyotrophic lateral sclerosis and other diseases with profound effect on quality of life and professional and social functioning.
- Conditions
- Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Stroke, Ischemic
- Trial name
- NCT06668649
- Testing
- Testing with Questionnaires
- Where
- 2 sites in Poland
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Jakub Antczak
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders
Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging
The MESO7 study is a prospective observational research project designed to investigate the mechanisms of resilience and neurodegeneration in neurological diseases and healthy aging.
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), Alzheimer Disease
- Trial name
- MESO7 (NCT07202494)
- Testing
- Imaging Techniques (MRI 3T & 7T, Functional, Structural, and Metabolic Imaging)
- Where
- France
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Amyotrophic Lateral Sclerosis
Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS
Phase II/III multicenter, randomized, double-blind, placebo-controlled trial on acetyl-L-carnitine (ALCAR) in subjects living with amyotrophic lateral sclerosis (ALS).
- Trial name
- ALCALS (NCT06126315)
- Testing
- Acetyl-l-carnitine
- Where
- 19 sites in Australia, Italy
- Volunteers
- 246 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Amyotrophic Lateral Sclerosis
Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative condition, mainly characterized by progressive weakness and wasting of the limbs, the respiratory and bulbar muscles.
- Trial name
- TIDALS (NCT05105958)
- Testing
- Tideglusib
- Where
- 5 sites in Switzerland
- Volunteers
- 98 people
- Sponsor
- University of Zurich
Amyotrophic Lateral Sclerosis
A Physiotherapy Intervention Study in Patients With Amyotrophic Lateral Sclerosis (ALS)
This study investigates whether an individualized physiotherapy program, tailored to each patient's specific motor deficits, can better support physical function compared with usual care physiotherapy in people with ALS.
- Trial name
- Train ALS (NCT07341984)
- Testing
- Individualized Physiotherapy
- Where
- Switzerland
- Volunteers
- 38 people
- Sponsor
- Charlotte Vogt
Amyotrophic Lateral Sclerosis (ALS)
Testing Pulse Stimulation to Improve Motor Function in People With ALS: A Pilot Study
The goal of this clinical trial is to assess the efficacy of TPS of the motor cortex on biomarkers and clinical endpoints in patients with ALS.
- Trial name
- TPS4ALS (NCT06681610)
- Testing
- Transcranial Pulse Stimulation
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Parc de Salut Mar
Amyotrophic Lateral Sclerosis (ALS)
Safety Study of XT-150 in Participants With ALS
This is a Phase 1, open-label, multi-center safety study of XT-150 in adult participants with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT06704347
- Testing
- XT-150
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Xalud Therapeutics, Inc.
Amyotrophic Lateral Sclerosis
A Registered Cohort Study on Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a kind of motor neuron degeneration disorder without effective therapy. This registered cohort study will provide further insights into the clinical course of ALS, and investigate…
- Trial name
- NCT04008329
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Amyotrophic Lateral Sclerosis, Pseudobulbar Affect
Structural and Functional Networks in ALS: An Insight Into Pseudobulbar Affect
The investigators aim to elucidate characteristics of structural and functional brain connectivity in patients with amyotrophic lateral sclerosis (ALS) and pseudobulbar affect (PBA) using diffusion kurtosis imaging (DKI) and…
- Trial name
- NCT06396260
- Testing
- Diffusion Kurtosis Imaging (DKI), Resting State Magnetoencephalography
- Where
- Denmark
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Aalborg University Hospital
Amyotrophic Lateral Sclerosis, Gastrointestinal Intolerance
Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in pALS
The main objective of the proposed study is to evaluate if oral intake of EN formula preceding Gtube placement will impact tolerance upon placement and feeding via Gtube in pALS.
- Conditions
- Amyotrophic Lateral Sclerosis, Gastrointestinal Intolerance, Enteral Nutrition Therapy
- Trial name
- NCT06609213
- Testing
- Medical Food
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Andrea Charvet
Amyotrophic Lateral Sclerosis
Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications
The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and age-matched speakers.
- Trial name
- NCT06266403
- Testing
- Structured Communicative Interaction, Clear Speech, Unstructured communicative interaction
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Penn State University
Tetraplegia/Tetraparesis, Quadriplegia
UAE-PRIME: A Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
The UAE-PRIME Study is a feasibility study designed to assess the initial clinical safety and functionality of the Neuralink N1 Implant and R1 Robot.
- Conditions
- Tetraplegia/Tetraparesis, Quadriplegia, Quadriplegia/Tetraplegia, Cervical Spinal Cord Injury
- Trial name
- UAE-PRIME (NCT06992596)
- Testing
- N1 Implant, R1 Robot
- Where
- United Arab Emirates
- Volunteers
- 10 people
- Sponsor
- Neuralink Corp